News >

Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma

Wayne Kuznar
Published: Wednesday, Sep 20, 2017

Cabozantinib (Cabometyx) and nivolumab (Opdivo) with or without ipilimumab (Yervoy) show activity in genitourinary (GU) tumors, particularly urothelial carcinoma, and have manageable safety profiles. The objective response rate (ORR) for all GU tumor types was 33% in 42 patients treated in a phase I trial.1 Final results from the trial were reported by Rosa Nadal, MD, a medical oncologist at the Center for Cancer Research, National Cancer Institute, Bethesda, MD at the 2017 ESMO Congress in Madrid, Spain.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Publication Bottom Border
Border Publication